Southern African journal of infectious diseases · 2020
Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ayten Omer, Saylan Bengu
Аннотация
BACKGROUND: Currently there is no proven medical treatment for COVID-19. We aimed to determine the factors affecting mortality and changes in clinical and laboratory findings in patients with severe COVID-19 pneumonia treated with lopinavir/ritonavir (Lpv/r).
METHODS: Data of survivor and non-survivor severe COVID-19 pneumonia patients treated with Lpv/r were analysed retrospectively.
RESULTS: A total of 73 patients, 26 (35.6%) females and 47 (64.4%) males were included in the study. The mean age of non-survivor and survivor patients was 64.3 ± 12 and 52.6 ± 12.2, respectively (p < 0.0001). Frequency of smoking and comorbid diseases was higher in non-survivor patients than in survivor patients (37% vs. 8.7% p = 0.003 and 92.6% vs. 28.3%, p < 0.0001, respectively). Age (Odds ratio [OR] 1.09, 95% confidence interval [95% CI] 1.03-1.14), smoking (OR 6.18, 1.7-22.42), presence of comorbid disease (OR 31.73, 6.26-153.56), coronary artery disease (OR 9.26, 1.79-47.77), arrhythmia (OR 13.8, 1.56-122.22), hypertension (OR 14, 4.28-45.74), diabetes (OR 7.22, 2-25.99) and congestive heart failure (OR 10.22, 1.13-92.93) were statistically associated with increased mortality (p < 0.05). Also increased neutrophil (OR 1.26, 1.08-1.46), C-reactive protein (CRP) (OR 1.01, 1.003-0.02), lactate dehydrogenase (LDH), (OR 1.002, 1.001-1.004), D-dimer (OR 1.001, 1.002-1.003), and aspartate transaminase (AST) levels (OR 1.05, 1.02-1.08 were associated with increased mortality.
CONCLUSION: The presence of advanced age, active smoking, comorbidity, especially hypertension, diabetes, arrhythmia, coronary artery disease, congestive heart failure and neutrophil, C-reactive protein, lactate dehydrogenase, D-dimer and aspartate transaminase were associated with mortality. The efficacy of Lpv/r, warrants further verification in future studies.
METHODS: Data of survivor and non-survivor severe COVID-19 pneumonia patients treated with Lpv/r were analysed retrospectively.
RESULTS: A total of 73 patients, 26 (35.6%) females and 47 (64.4%) males were included in the study. The mean age of non-survivor and survivor patients was 64.3 ± 12 and 52.6 ± 12.2, respectively (p < 0.0001). Frequency of smoking and comorbid diseases was higher in non-survivor patients than in survivor patients (37% vs. 8.7% p = 0.003 and 92.6% vs. 28.3%, p < 0.0001, respectively). Age (Odds ratio [OR] 1.09, 95% confidence interval [95% CI] 1.03-1.14), smoking (OR 6.18, 1.7-22.42), presence of comorbid disease (OR 31.73, 6.26-153.56), coronary artery disease (OR 9.26, 1.79-47.77), arrhythmia (OR 13.8, 1.56-122.22), hypertension (OR 14, 4.28-45.74), diabetes (OR 7.22, 2-25.99) and congestive heart failure (OR 10.22, 1.13-92.93) were statistically associated with increased mortality (p < 0.05). Also increased neutrophil (OR 1.26, 1.08-1.46), C-reactive protein (CRP) (OR 1.01, 1.003-0.02), lactate dehydrogenase (LDH), (OR 1.002, 1.001-1.004), D-dimer (OR 1.001, 1.002-1.003), and aspartate transaminase (AST) levels (OR 1.05, 1.02-1.08 were associated with increased mortality.
CONCLUSION: The presence of advanced age, active smoking, comorbidity, especially hypertension, diabetes, arrhythmia, coronary artery disease, congestive heart failure and neutrophil, C-reactive protein, lactate dehydrogenase, D-dimer and aspartate transaminase were associated with mortality. The efficacy of Lpv/r, warrants further verification in future studies.